You are here

MMDR: Advertising reforms

15 July 2020

Reforms to the regulatory framework for advertising of therapeutic goods are being implemented in response to the recommendations arising from the Review of Medicines and Medical Devices Regulation.

The reforms include changes that will streamline complaints handling, enhance sanctions and penalties available for addressing non-complaint advertising, and abolish the requirement for certain advertisements to be pre-approved.

Advertising hub

The advertising hub contains tools for both consumers and advertisers around the changes to the framework for advertising therapeutic goods, including fact sheets, e-learning modules and forms for reporting illegal advertising and submitting enquiries.

Simplified arrangements for handling advertising complaints

The Therapeutic Goods Administration is now responsible for receiving and considering all complaints about therapeutic goods advertisements directed to the public under a simplified complaints system.

Enhanced sanctions and penalties

Introduction of stronger compliance and enforcement tools to address non-compliant advertising of therapeutic goods through a graduated approach.

Therapeutic Goods Advertising Code 2018

The Therapeutic Goods Advertising Code has been updated to ensure that the marketing and advertising of therapeutic goods is conducted in a manner that promotes the quality use of the product, is socially responsible and does not mislead or deceive the consumer.

Requirement for advertising pre-approval

Legislative changes are in place to streamline the process of advertising therapeutic goods to the public and provide advertising consistency for medicines and medical devices.